Streetbeat News

Analyst Ratings

PCG

Mizuho analyst Paul Fremont has maintained a Buy rating on PG&E Corporation (NYSE:PCG) and increased the price target from $19 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:32 pm

AMAT

Mizuho analyst Vijay Rakesh has maintained a Buy rating on Applied Materials (NASDAQ:AMAT) and increased the price target from $162 to $167, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:30 pm

ALEC

Mizuho analyst Graig Suvannavejh has maintained a Buy rating on Alector (NASDAQ:ALEC) but reduced the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:28 pm

NVDA

Piper Sandler analyst Harsh Kumar has reiterated an Overweight rating on NVIDIA (NASDAQ:NVDA) and maintained a price target of $620 for the stock.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:24 pm

SOFI

Piper Sandler analyst Kevin Barker has maintained a Neutral rating on SoFi Technologies (NASDAQ:SOFI) but reduced the price target from $9 to $8.5.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:20 pm

GPS

Gap Inc. (NYSE:GPS) reported Q3 earnings of $0.59 per share, surpassing the consensus estimate of $0.18. Sales were $3.767 billion, above expectations of $3.610 billion but down 7% from the previous year. Following the report, Gap's stock surged 30% to $17.76. Analysts from Telsey Advisory Group, Morgan Stanley, Wells Fargo, Goldman Sachs, and BMO Capital revised their price targets upwards while maintaining their respective ratings.

Portfolio Pulse from Lisa Levin

November 17, 2023 | 5:19 pm

PACB

Pacific Biosciences (PACB) stock is trading higher following an upgrade from UBS, which changed its rating from Neutral to Buy. However, UBS also reduced the price target for PACB from $13 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:18 pm

ICVX

Icosavax's stock (ICVX) is trading higher following Guggenheim's initiation of coverage with a Buy rating and a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:17 pm

DRTS

Piper Sandler analyst Jason Bednar has maintained an Overweight rating on Alpha Tau Medical (NASDAQ:DRTS) but reduced the price target from $12 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:15 pm

KRTX

JMP Securities analyst Jason Butler has reiterated a 'Market Outperform' rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a price target of $318.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:13 pm